ATE328605T1 - Verwendung von insulin zur behandlung von knorpelkrankheiten - Google Patents

Verwendung von insulin zur behandlung von knorpelkrankheiten

Info

Publication number: ATE328605T1
Authority: AT; Austria
Prior art keywords: insulin; administration; cartilage; injury; repair
Prior art date: 2000-03-24

Application number

AT01922571T

Other languages

English (en)

Inventor

Ellen H Filvaroff

Franklin W Okumu

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-24

Filing date

2001-03-22

Publication date

2006-06-15

2001-03-22 Application filed by Genentech Inc filed Critical Genentech Inc

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE328605T1 publication Critical patent/ATE328605T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 14
102000004877 Insulin Human genes 0.000 title abstract 7
108090001061 Insulin Proteins 0.000 title abstract 7
229940125396 insulin Drugs 0.000 title abstract 7
208000015100 cartilage disease Diseases 0.000 title 1
210000000845 cartilage Anatomy 0.000 abstract 5
208000027418 Wounds and injury Diseases 0.000 abstract 3
230000006378 damage Effects 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000014674 injury Diseases 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
239000005557 antagonist Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
210000001612 chondrocyte Anatomy 0.000 abstract 1
238000013265 extended release Methods 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Microbiology (AREA)
Dermatology (AREA)
Neurology (AREA)
Mycology (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Child & Adolescent Psychology (AREA)

AT01922571T 2000-03-24 2001-03-22 Verwendung von insulin zur behandlung von knorpelkrankheiten ATE328605T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19210300P	2000-03-24	2000-03-24

Publications (1)

Publication Number	Publication Date
ATE328605T1 true ATE328605T1 (de)	2006-06-15

Family

ID=22708258

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01922571T ATE328605T1 (de)	2000-03-24	2001-03-22	Verwendung von insulin zur behandlung von knorpelkrankheiten

Country Status (11)

Country	Link
US (4)	US6689747B2 (de)
EP (1)	EP1265630B1 (de)
JP (2)	JP2003528149A (de)
AT (1)	ATE328605T1 (de)
AU (1)	AU4935701A (de)
CA (1)	CA2402191C (de)
DE (1)	DE60120372T2 (de)
DK (1)	DK1265630T3 (de)
ES (1)	ES2266187T3 (de)
IL (1)	IL151408A (de)
WO (1)	WO2001072323A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7019192B2 (en) *	1998-02-27	2006-03-28	Musculoskeletal Transplant Foundation	Composition for filling bone defects
US20050147609A1 (en) *	1998-05-15	2005-07-07	Genentech, Inc.	Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
DE60120372T2 (de) *	2000-03-24	2007-07-05	Genentech Inc., San Francisco	Verwendung von insulin zur behandlung von knorpelkrankheiten
US7090865B2 (en) *	2001-11-29	2006-08-15	National Jewish Medical And Research Center	Composition and method for treating autoimmune hemolytic anemia
US20040005999A1 (en) *	2002-03-07	2004-01-08	Andreasen Kasper Huus	Polyamino acid-based particle insulin preparation
US20060204544A1 (en) *	2002-05-20	2006-09-14	Musculoskeletal Transplant Foundation	Allograft bone composition having a gelatin binder
US20040138116A1 (en) *	2002-08-30	2004-07-15	Vincent Geenen	Tolerogenic approach for type 1 diabetes
US20070122487A1 (en) *	2003-03-19	2007-05-31	University Of Kentucky Research Foundation	(Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
EP1617888B1 (de)	2003-04-23	2019-06-12	Valeritas, Inc.	Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
US20050222687A1 (en) *	2004-04-02	2005-10-06	Gordana Vunjak-Novakovic	Cartilage implant assembly and method for implantation
US7067123B2 (en) *	2003-04-29	2006-06-27	Musculoskeletal Transplant Foundation	Glue for cartilage repair
US20050064042A1 (en) *	2003-04-29	2005-03-24	Musculoskeletal Transplant Foundation	Cartilage implant plug with fibrin glue and method for implantation
US20040228897A1 (en) *	2003-05-16	2004-11-18	Zhang Ping Ye	Methods and apparatus for in vivo cell localization
US20090291112A1 (en) *	2003-05-16	2009-11-26	Truncale Katherine G	Allograft osteochondral plug combined with cartilage particle mixture
US7488348B2 (en) *	2003-05-16	2009-02-10	Musculoskeletal Transplant Foundation	Cartilage allograft plug
US7901457B2 (en) *	2003-05-16	2011-03-08	Musculoskeletal Transplant Foundation	Cartilage allograft plug
WO2005066215A1 (en) *	2003-12-30	2005-07-21	Genzyme Corporation	Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
GB0402129D0 (en) *	2004-01-30	2004-03-03	King S College London	Therapeutic and diagnostic peptides
WO2006014425A1 (en) *	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
US8512730B2 (en) *	2004-07-12	2013-08-20	Isto Technologies, Inc.	Methods of tissue repair and compositions therefor
EP1773299B1 (de) *	2004-07-12	2017-07-05	Isto Technologies Inc.	Gewebematrixsystem
US8697139B2 (en)	2004-09-21	2014-04-15	Frank M. Phillips	Method of intervertebral disc treatment using articular chondrocyte cells
US7837740B2 (en)	2007-01-24	2010-11-23	Musculoskeletal Transplant Foundation	Two piece cancellous construct for cartilage repair
US20080220044A1 (en) *	2007-03-06	2008-09-11	Semler Eric J	Cancellous construct with support ring for repair of osteochondral defects
WO2006061824A2 (en) *	2004-12-06	2006-06-15	Prochon Biotech Limited	Chondrocyte-based implant for the delivery of therapeutic agents
US7815926B2 (en) *	2005-07-11	2010-10-19	Musculoskeletal Transplant Foundation	Implant for articular cartilage repair
JP2009508596A (ja)	2005-09-19	2009-03-05	ヒストジェニックスコーポレイション	細胞支持基材及びその調製方法
JP2009518132A (ja) *	2005-12-07	2009-05-07	イスト・テクノロジーズ・インコーポレイテッド	軟骨修復方法
US20070141160A1 (en) *	2005-12-15	2007-06-21	Brown Laura J	Method of treatment for osteoarthritis by local intra-articular injection of microparticles
KR101361376B1 (ko)	2006-03-30	2014-02-10	발레리타스 인코포레이티드	복합-카트리지 유체 전달 장치
HUE026001T2 (en)	2007-02-05	2016-04-28	Apellis Pharmaceuticals Inc	Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US8435551B2 (en) *	2007-03-06	2013-05-07	Musculoskeletal Transplant Foundation	Cancellous construct with support ring for repair of osteochondral defects
WO2008130158A1 (en) *	2007-04-19	2008-10-30	Dong-A Pharmaceutical. Co., Ltd	A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
WO2008134054A1 (en) *	2007-04-26	2008-11-06	Genera Doo	Blood biomarkers for bone fracture and cartilage injury
US20090054984A1 (en)	2007-08-20	2009-02-26	Histogenics Corporation	Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en)	2007-07-03	2014-04-01	Histogenics Corporation	Double-structured tissue implant and a method for preparation and use thereof
CA2708147A1 (en) *	2007-12-05	2009-06-18	Musculoskeletal Transplant Foundation	Cancellous bone implant for cartilage repair
WO2009111069A1 (en)	2008-03-05	2009-09-11	Musculoskeletal Transplant Foundation	Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
RU2474588C2 (ru)	2008-05-05	2013-02-10	Новиммун Са	Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
WO2010014446A1 (en) *	2008-07-28	2010-02-04	Zimmer, Inc.	Mosaicplasty constructs
US8263069B2 (en) *	2008-12-31	2012-09-11	Johnson Lanny L	Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions
CN102458437B (zh)	2009-05-05	2015-06-10	诺维莫尼公司	抗il-17f抗体及其使用方法
WO2010135717A2 (en)	2009-05-21	2010-11-25	Potentia Pharmaceuticals, Inc.	Complement assays and uses thereof
JP2013512674A (ja) *	2009-12-02	2013-04-18	アクセルロンファーマ，インコーポレイテッド	Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
JP2013535467A (ja)	2010-07-28	2013-09-12	スマートセルズ・インコーポレイテツド	組換えにより発現されたインスリンポリペプチドおよびその使用
EP2718328A4 (de)	2011-06-08	2014-12-24	Acceleron Pharma Inc	Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
AR087433A1 (es) *	2011-08-08	2014-03-26	Merck Sharp & Dohme	Analogos de insulina n-glicosilados
EP2804621A4 (de) *	2012-01-20	2015-11-18	Univ Case Western Reserve	Glutaminsäurestabilisierte insulinanaloga
US10245306B2 (en)	2012-11-16	2019-04-02	Isto Technologies Ii, Llc	Flexible tissue matrix and methods for joint repair
US9968623B2 (en)	2013-08-29	2018-05-15	Lanny Leo Johnson	Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
US10457716B2 (en) *	2014-08-06	2019-10-29	University Of Notre Dame Du Lac	Protein folding and methods of using same
US10179191B2 (en)	2014-10-09	2019-01-15	Isto Technologies Ii, Llc	Flexible tissue matrix and methods for joint repair
US11925656B2 (en) *	2014-11-05	2024-03-12	Lanny Leo Johnson	Biological total joint replacement
US10077420B2 (en)	2014-12-02	2018-09-18	Histogenics Corporation	Cell and tissue culture container
PE20210857A1 (es)	2016-12-16	2021-05-18	Novo Nordisk As	Composiciones farmaceuticas que contienen insulina
EP3773298A1 (de)	2018-04-03	2021-02-17	Convergent Dental, Inc.	Lasersystem für chirurgische anwendungen

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US544047A (en) *		1895-08-06		Rheostat
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4430266A (en) *	1980-11-28	1984-02-07	Eli Lilly And Company	Process for producing an insulin precursor
NZ199391A (en)	1981-01-02	1985-12-13	Genentech Inc	Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
FI78616C (fi) *	1982-02-05	1989-09-11	Novo Industri As	Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4530840A (en) *	1982-07-29	1985-07-23	The Stolle Research And Development Corporation	Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4622219A (en) *	1983-06-17	1986-11-11	Haynes Duncan H	Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) *	1983-06-17	1988-02-16	Haynes Duncan H	Microdroplets of water-insoluble drugs and injectable formulations containing same
US4891225A (en) *	1984-05-21	1990-01-02	Massachusetts Institute Of Technology	Bioerodible polyanhydrides for controlled drug delivery
DK58285D0 (da)	1984-05-30	1985-02-08	Novo Industri As	Peptider samt fremstilling og anvendelse deraf
US4569791A (en)	1984-06-14	1986-02-11	Eli Lilly And Company	Anti-diabetic compounds
US4569792A (en)	1984-06-14	1986-02-11	Eli Lilly And Company	Anti-diabetic compounds
US4581165A (en)	1984-06-14	1986-04-08	Eli Lilly And Company	Anti-diabetic compounds
WO1986001540A1 (en)	1984-08-31	1986-03-13	Genetics Institute, Inc.	Modified insulin precursors products and processes
DK129385A (da)	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
IT1198449B (it) *	1986-10-13	1988-12-21	F I D I Farmaceutici Italiani	Esteri di alcoli polivalenti di acido ialuronico
CA1340772C (en)	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
DK257988D0 (da)	1988-05-11	1988-05-11	Novo Industri As	Nye peptider
DE3837825A1 (de) *	1988-11-08	1990-05-10	Hoechst Ag	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
HUT56857A (en)	1988-12-23	1991-10-28	Novo Nordisk As	Human insulin analogues
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
US5019400A (en) *	1989-05-01	1991-05-28	Enzytech, Inc.	Very low temperature casting of controlled release microspheres
SE500903C2 (sv)	1989-12-20	1994-09-26	Atlas Copco Constr & Mining	Bergborrningsrigg
NZ236618A (en)	1990-01-03	1997-06-24	Ciba Geigy Ag	Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5364839A (en)	1990-06-18	1994-11-15	Genetics Institute, Inc.	Osteoinductive pharmaceutical formulations
US5206023A (en)	1991-01-31	1993-04-27	Robert F. Shaw	Method and compositions for the treatment and repair of defects or lesions in cartilage
IL102240A0 (en)	1991-06-21	1993-01-14	Lilly Co Eli	Insulin analogs
US5378613A (en)	1991-09-24	1995-01-03	Eli Lilly And Company	Method for increased expression of low molecular weight recombinant polypeptides
NZ245170A (en)	1991-11-26	1994-07-26	Lilly Co Eli	Insulin and proinsulin analogues with arg at b31, b32 and ao and pharmaceutical compositions
GB9204155D0 (en)	1992-02-27	1992-04-08	Amp Gmbh	Improved latching mechanism for blindmate electrical connectors
TW267102B (de)	1992-03-13	1996-01-01	Ciba Geigy
DE4208552A1 (de) *	1992-03-17	1993-09-23	Liedtke Pharmed Gmbh	Topische arzneiformen mit insulin
NZ255461A (en)	1992-08-20	1996-12-20	Biotechnology & Biolog Science	Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
CA2150803C (en) *	1992-12-02	2006-01-31	Henry Auer	Controlled release growth hormone containing microspheres
US5534488A (en) *	1993-08-13	1996-07-09	Eli Lilly And Company	Insulin formulation
US5506302A (en) *	1993-09-10	1996-04-09	Shin-Etsu Chemical Co., Inc.	Organopolysiloxane composition and rubber substrate having a coating thereof
EP1132404A3 (de)	1993-09-17	2002-03-27	Novo Nordisk A/S	Acyliertes Insulin
BR9400600A (pt)	1994-02-17	1995-10-24	Finep Financiadora De Estudos	Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US5597700A (en) *	1994-04-28	1997-01-28	California Research, Llc	Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en)	1994-06-16	1995-08-22	Dipasquale; Gene	Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
US5559094A (en)	1994-08-02	1996-09-24	Eli Lilly And Company	AspB1 insulin analogs
HRP940432B1 (en)	1994-08-05	2003-10-31	Pliva Pharm & Chem Works	Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
PT779806E (pt)	1994-09-09	2001-02-28	Takeda Chemical Industries Ltd	Preparacao de libertacao sustentada contendo um sal metalico de um peptido
BR9408638A (pt)	1994-12-29	2004-09-21	Bio Technology General Corp	Geração de insulina humana
US5686113A (en) *	1995-03-21	1997-11-11	Temple University Of The Commonwealth System Of Higher Education	Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
PT831787E (pt)	1995-06-07	2002-02-28	Alkermes Inc	Composicao para libertacao sustentada da hormona de crescimento humano
ZA965368B (en)	1995-07-14	1997-01-14	Novo Nordisk As	A pharmaceutical formulation
US6190702B1 (en)	1996-03-28	2001-02-20	Takeda Chemical Industries, Ltd.	Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
CA2224859A1 (en)	1996-04-17	1997-10-23	Amitabh Gaur	Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en)	1997-04-04	2000-09-19	Genentech, Inc.	Insulin-like growth factor agonist molecules
US6004573A (en) *	1997-10-03	1999-12-21	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AU3548999A (en) *	1998-04-03	1999-10-25	Chiron Corporation	Use of igfi for treating articular cartilage disorders
AU763039B2 (en) *	1999-04-08	2003-07-10	Genentech Inc.	Composition based on oppositely-charged polypeptides
DE60120372T2 (de) *	2000-03-24	2007-07-05	Genentech Inc., San Francisco	Verwendung von insulin zur behandlung von knorpelkrankheiten

2001
- 2001-03-22 DE DE60120372T patent/DE60120372T2/de not_active Expired - Lifetime
- 2001-03-22 DK DK01922571T patent/DK1265630T3/da active
- 2001-03-22 US US09/815,229 patent/US6689747B2/en not_active Expired - Lifetime
- 2001-03-22 WO PCT/US2001/009230 patent/WO2001072323A2/en not_active Ceased
- 2001-03-22 AU AU4935701A patent/AU4935701A/xx active Pending
- 2001-03-22 EP EP01922571A patent/EP1265630B1/de not_active Expired - Lifetime
- 2001-03-22 AT AT01922571T patent/ATE328605T1/de active
- 2001-03-22 JP JP2001570284A patent/JP2003528149A/ja not_active Withdrawn
- 2001-03-22 ES ES01922571T patent/ES2266187T3/es not_active Expired - Lifetime
- 2001-03-22 CA CA2402191A patent/CA2402191C/en not_active Expired - Fee Related
2002
- 2002-08-21 IL IL151408A patent/IL151408A/en not_active IP Right Cessation
2003
- 2003-12-17 US US10/740,098 patent/US7268112B2/en not_active Expired - Fee Related
2006
- 2006-10-04 US US11/538,700 patent/US20070049516A1/en not_active Abandoned
2010
- 2010-06-28 US US12/825,208 patent/US20100266698A1/en not_active Abandoned
2012
- 2012-01-27 JP JP2012015753A patent/JP2012121896A/ja not_active Ceased

Also Published As

Publication number	Publication date
WO2001072323A3 (en)	2002-06-06
WO2001072323A2 (en)	2001-10-04
US20040138101A1 (en)	2004-07-15
US20020058614A1 (en)	2002-05-16
CA2402191C (en)	2012-03-13
IL151408A (en)	2009-08-03
US7268112B2 (en)	2007-09-11
IL151408A0 (en)	2003-04-10
ES2266187T3 (es)	2007-03-01
US20100266698A1 (en)	2010-10-21
EP1265630A2 (de)	2002-12-18
CA2402191A1 (en)	2001-10-04
AU4935701A (en)	2001-10-08
DK1265630T3 (da)	2006-10-09
DE60120372D1 (de)	2006-07-20
DE60120372T2 (de)	2007-07-05
JP2003528149A (ja)	2003-09-24
EP1265630B1 (de)	2006-06-07
US6689747B2 (en)	2004-02-10
JP2012121896A (ja)	2012-06-28
US20070049516A1 (en)	2007-03-01

Legal Events

Date

Code

Title

Description

2007-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1265630

Country of ref document: EP

Publication	Publication Date	Title
ATE328605T1 (de)	2006-06-15	Verwendung von insulin zur behandlung von knorpelkrankheiten
IL200484A0 (en)	2010-04-29	Use of wisp polypeptides wisp for the preparation of medicaments
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE362363T1 (de)	2007-06-15	Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69616376D1 (de)	2001-11-29	Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69733132D1 (de)	2005-06-02	Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69729125D1 (de)	2004-06-17	Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
EA200300929A1 (ru)	2004-04-29	Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
PT881908E (pt)	2004-11-30	Utilizacao dos factores de crescimento de fibroblasto para estimular o crescimento osseo
ATE315390T1 (de)	2006-02-15	Zyklische polyamine zur behandlung der thrombozytopenie
ATE399782T1 (de)	2008-07-15	Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE60008753D1 (de)	2004-04-08	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60140960D1 (de)	2010-02-11	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE281841T1 (de)	2004-11-15	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE332688T1 (de)	2006-08-15	Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE268170T1 (de)	2004-06-15	Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
DE59510674D1 (de)	2003-06-12	Verwendung von selegilin zur behandlung von epileptischen erkrankungen
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
ATE295731T1 (de)	2005-06-15	Olanzapine zur behandlung von drogenmissbrauch
DE60108775D1 (de)	2005-03-10	Methode zur behandlung von schlaganfall
DE69941134D1 (de)	2009-08-27	Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
DE69832796D1 (de)	2006-01-19	Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen